Patrick Langlois

Patrick J.
Langlois is currently Chairman at ArkAb SAS since 2018, General Partner at PJL Consulting since 2005, and General Partner at DFC Langlois.
Former roles include Non-Executive Chairman at Stallergenes SAS from 2011 to 2015, Chairman at Valerio Therapeutics SA from 2011 to 2016, Vice Chairman-Supervisory Board at Exonhit, Independent Chairman at Sensorion SA from 2015 to 2020, Chairman at B Cell Design SAS, Vice Chairman-Supervisory Board at Eurobio-Scientific SA from 2012 to 2014, Vice Chairman at Stallergenes Greer Ltd., Director at Shire Plc from 2005 to 2008, Director at Coley Pharmaceutical Group, Inc., Non-Executive Director at Shire Acquisition, Inc., Director at Shire Plc from 2005 to 2009, Independent Director at SCYNEXIS, Inc., Director at Curium PET France, Independent Non-Executive Director at Newron Pharmaceuticals SpA from 2008 to 2026, Chief Financial Officer & Group Executive VP at Aventis SA from 1999 to 2004, Chief Financial Officer at Rhone-Poulenc Rorer, Inc. in 1999, Independent Member-Supervisory Board at Innate Pharma SA from 2010 to 2022, President at DrugAbuse Sciences SAS, and President at Nanobiotix SA. Education includes a doctorate and undergraduate degree from the University of Rennes.